Sign In
Buy ORMP
$4.07
-0.0500 (-1.21%)
At Close: Jul 31, 2026
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
08:40am, Wednesday, 28'th Oct 2020
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive
How Much Is Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CEO Getting Paid?
04:20pm, Tuesday, 11'th Aug 2020
This article will reflect on the compensation paid to Nadav Kidron who has served as CEO of Oramed Pharmaceuticals...
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Expected to Announce Quarterly Sales of $690,000.00
11:36pm, Sunday, 09'th Aug 2020
Wall Street brokerages expect Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) to announce $690,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have prov
The North America hypertriglyceridemia therapeutics market is estimated to be the most lucrative during the period of forecast.
Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright - Markets
10:21am, Monday, 20'th Jul 2020
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report) today and set a
Company News for Jul 16, 2020
02:19pm, Thursday, 16'th Jul 2020
Companies in the new are: INFY, PGR, BE, ORMP
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
12:55pm, Wednesday, 15'th Jul 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA
Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright - Markets
11:52am, Monday, 13'th Jul 2020
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report) today and set a
Oramed Pharmaceuticals (NASDAQ:ORMP) Receives “Buy” Rating from HC Wainwright
07:28am, Monday, 13'th Jul 2020
Oramed Pharmaceuticals (NASDAQ:ORMP)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Monday, The Fly reports. They presently have a $17.00 pri
Insulin in Pill Form Would Be a Bonanza for Oramed
10:09pm, Wednesday, 08'th Jul 2020
Drug trials suggest first commercial oral insulin capsule may be on the horizon Continue reading...
Legal teams discover their inner geek
03:30am, Friday, 26'th Jun 2020
Lawyers who merge business, law and technology are redefining corporate legal departments. Plus: five general counsel who stand out for developing new products
HC Wainwright Reiterates “Buy” Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)
02:32am, Wednesday, 24'th Jun 2020
Oramed Pharmaceuticals (NASDAQ:ORMP)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Marketbeat report
ORMP: Positive Takeaways of Preliminary NASH Study Findings
09:34am, Friday, 19'th Jun 2020
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technolo
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
12:25pm, Monday, 15'th Jun 2020
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pil
